Affiliations 

  • 1 Department of Pharmacy, Birla Institute of Technology & Science (BITS), Pilani, Pilani Campus, Rajasthan, 333031, India
  • 2 Department of Pharmacy, Birla Institute of Technology & Science (BITS), Pilani, Pilani Campus, Rajasthan, 333031, India. Electronic address: gautam.singhvi@pilani.bits-pilani.ac.in
  • 3 School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, 302017, Jaipur, India. Electronic address: gauravpharma25@gmail.com
  • 4 Department of Life Sciences, International Medical University, Kuala Lumpur, 57000, Malaysia
  • 5 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo NSW 2007, Australia; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW 2308, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, Lot 1 Kookaburra Circuit, New Lambton Heights, Newcastle, NSW 2305, Australia
Biomed Pharmacother, 2018 Oct;106:707-713.
PMID: 29990862 DOI: 10.1016/j.biopha.2018.06.136

Abstract

Psoriasis is a chronic autoimmune skin disorder affecting 2-3% of the world population. It has characteristic features such as increased keratinocyte proliferation and production of inflammatory mediators. The treatment involves various strategies including topical, systemic, phototherapy and biologics. Topical therapies are preferred for mild to moderate psoriasis conditions over the systemic therapies which are ideal in severe disease conditions. The systemic therapies include immunosuppressants, biological agents and recently approved phosphodiesterase-4 (PDE4) inhibitors. There are various limitations associated with the existing therapies where the new findings in the pathogenesis of psoriasis are paving a path for newer therapeutics to target at the molecular level. Various small molecules, PDE-4 inhibitors, biologics, and immunomodulator proved efficacious including the new molecules targeting Janus kinases (JAK) inhibitors that are under investigation. Furthermore, the role of genetic and miRNAs in psoriasis is still not completely explored and may further help in improving the treatment efficacy. This review provides an insight into various emerging therapies along with currently approved treatments for psoriasis.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.